OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

Trustees’ Annual Report for the period

From 01.01.2024 Period start date To 31.12.2024 Period end date Charity name: UK Acute Oncology Society

Charity registration number: 1199351

Objectives and Activities

SORP reference
Summary of the purposes of
the charity as set out in its
governing document
Para 1.17 •For the public benefit, to advance the
education of all healthcare professionals
involved in treating or supporting patients
in the field of acute oncology.
•In furtherance of the object above, to
promote research for the public benefit in
all aspects of that subject and to publish
the useful results.
•The relief of sickness and preservation of
health, from cancer, among people
residing permanently or temporarily in the
UK.
•To assist in the treatment and care of
persons suffering from cancer, or in need
of rehabilitation, by the provision of
education for healthcare professionals.
•To promote the wellbeing of people
suffering from acute effects of cancer
and/or anti-cancer treatment and support
the development of acute oncology
services in the UK through assisting in
the provision of education.
Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.
Para 1.17 and
1.19
1. Provision of forum for Health Care
professionals
supporting
emergency
cancer care.
2. Annual educational programme.
3. Website and educational resources.
4. Supporting service innovation, shared
learning and research promotion.
Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit
Para 1.18 The UKAOS trustees have had regard to the
guidance issued by the Charity Commission
on public benefit.

Additional information (optional) You may choose to include further statements where relevant about:

SORP reference

Para 1.38 Policy on grant making Para 1.38 Policy on social investment including program related investment Para 1.38 Contribution made by volunteers Other

Achievements and Performance

SORP reference
Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.
Para 1.20 Ongoing UKAOS Governance Review
The UKAOS initiated a Trustee rotation as
per the constitution with 3 new Trustees
appointed and 2 Trustee farewells.
As part of a wider Governance review, a
newly established Programme Management
Group (Nov 23) conducted a review of
UKAOS Subgroups with refreshed Terms of
Reference and several significant changes
in line with the evolving UKAOS priorities
including:
Closure of the trainee subgroup (in favour of
integrating trainees across all groups).
Closure
of
the
Radiotherapy
Toxicity
subgroup (in favour of an amalgamated
approach to Treatment Toxicity).
Launch of 3 new Subgroups: Nursing,
Malignancy of Unknown origin (MUO) and
Metastatic
Spinal
Cord
Compression
(MSCC)

each
recognising
national
leadership in these areas from UKAOS.
UKAOS Influence
Development and stakeholder engagement
of the first UKAOS 5-year Strategy (2025-
2030) – subsequently published 2025.
UKAOS engagement with NHS England
successfully delivering Oncology as a core
component
of
national
Same
Day
Emergency Care (SDEC) Strategy.
4 Nation Cancer Hotline Review – national
survey and analysis 2024.
Formal agreement for UKAOS clinical
representation
at
national
bodies
(Association of Cancer Physicians, Royal
College of Radiologists).
First national Acute Oncology Week 7-11th
Oct 24.
UKAOS Board member awarded MBE.
Successful Launch of first ever Nepal Acute
Oncology Service Model with UKAOS
support.
UKAOS Education & Training
Successful delivery of a national 1-day
UKAOS Conference (Sept 24).
Co Chairmanship and launch of National
Acute Oncology Education Group.
Successful sessional delivery of UKAOS at
national conferences (UK Oncology Forum
June 24, UK SACT Board Nov 24), Society
of Acute Medicine AO Webinar Dec 24.
UKAOS agreement to deliver monthly online
learning hour through 2025.

Additional information (optional) You may choose to include further statements where relevant about:

Achievements against
objectives set
Para 1.41
Performance of fundraising
activities against objectives
set
Para 1.41
Investment performance
against objectives
Para 1.41

Other

Financial Review

Financial Review
Review of the charity’s
financial position at the end
of the period
Para 1.21 Details of receipts and payments are given
in the Receipts and Payments Account
within the financial statements. The total
unrestricted funds as at 31 December 2024
amounted to £4,755 (2023: £20,074)
Statement explaining the
policy for holding reserves
stating why they are held
Para 1.22 To fund future projects.
Amount of reserves held Para 1.22 The free reserves at 31 December 2024 are
£4,755 (2023: £14,074) and the trustees are
satisfied that this level of reserves is
sufficient to meet the needs of the charity in
its early stages of development.
Reasons for holding zero
reserves
Para 1.22 Not applicable.
Details of fund materially in
deficit
Para 1.24 None.
Explanation of any
uncertainties about the
charity continuing as a going
concern
Para 1.23 There are no uncertainties about the charity
continuing as a going concern.

Additional information (optional) You may choose to include further statements where relevant about:

The charity’s principal
sources of funds (including
any fundraising)
Para 1.47
Investment policy and
objectives including any
social investment policy
adopted
Para 1.46
A description of the principal
risks facing the charity
Para 1.46
Other

Structure, Governance and Management

Description of charity’s
trusts:
Type of governing document
(trust deed, royal charter)
Para 1.25 Constitution.
How is the charity
constituted?
(e.g unincorporated
association, CIO)
Para 1.25 Charitable Incorporated Organisation (CIO)
Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees
Para 1.25 Election by UKAOS members at Annual
General Meeting.

Additional information (optional) You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction Para 1.51 and training of trustees The charity’s organisational structure and any wider Para 1.51 network with which the charity works Relationship with any related Para 1.51 parties Other

Reference and Administrative details

Charity name UK Acute Oncology Society
Other name the charity uses UKAOS
Registered charity number 1199351
Charity’s principal address UKAOS Secretariat
c/o Media1 Productions Ltd
Clarence Mill, Clarence Road
Bollington
Macclesfield
SK10 5JZ

Names of the charity trustees who manage the charity

Trustee name Office (if any)

Dates acted if not for whole year

Name of person (or body) entitled to appoint trustee (if any)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Dr E Marshall Chair
Dr C Mitchell Upto 1.9.24
Dr H J Williams Treasurer
P J Jones
N R Clatworthy Upto 1.9.24
Dr C Wilson Secretary
J Upton From 1.9.24
D Munro From 1.9.24
P Gillis From 1.9.24

– Corporate trustees names of the directors at the date the report was approved

Director name

Name of trustees holding title to property belonging to the charity

Trustee name Dates acted if not for whole year

Funds held as custodian trustees on behalf of others

Description of the assets None. held in this capacity Name and objects of the Not applicable. charity on whose behalf the assets are held and how this falls within the custodian charity’s objects

Details of arrangements for Not applicable. safe custody and segregation of such assets from the charity’s own assets

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of Name Address adviser

Name of chief executive or names of senior staff members (Optional information)

Exemptions from disclosure

Reason for non-disclosure of key personnel details Not applicable.

Other optional information

Not applicable

Declarations

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

Signature(s) Full name(s) Dr ERNEST MARSHALL Position (eg Secretary, Chair, etc) Chair Date 24/10/2025

UK Acute Oncology Society (UKAOS)
Charity Name
UK Acute Oncology Society (UKAOS)
Charity Name
UK Acute Oncology Society (UKAOS)
Charity Name
1199351
No (if any)
1199351
No (if any)
1199351
No (if any)
CC16a
For the period
from
01-Jan-24
Period start date
To 31-Dec-24
Period end date
Section A Receipts and payments
A1 Receipts Unrestricted
funds
to the nearest £
14,000
-
-
-
-
-
-
-
14,000
4,800
-
4,800
18,800
265
848
21,306
900
10,800
-
-
-
-
34,119
-
-
-
34,119
- 15,319
-
20,074
4,755
Restricted
funds
to the nearest £
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Endowment
funds
to the nearest £
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Total funds
to the nearest £
14,000
-
-
-
-
-
-
-
14,000
4,800
-
4,800
18,800
265
848
21,306
900
10,800
-
-
-
-
34,119
-
-
-
34,119
- 15,319
Last year
to the nearest £
Sponsorships and grants 14,000 20,000
- -
- -
- -
- -
- -
- -
- -
Sub total(Gross income for
AR)
14,000 20,000
Fundsreceivedinerror 4,800 6,000
- -
Sub total 4,800 6,000
Total receipts
A3 Payments
26,000

Bank charges
265 300

Website expenses
848 2,058

Secretariat
21,306 **7,162 **
Accountancy 900 900
Repayment for funds received in
error
10,800 -
- -
- -
- -
- -
**Sub total ** 34,119 10,420
A4 Asset and investment
purchases (see table)
, -
-
**Sub total ** - -
Total payments
Net of receipts/(payments)
A5 Transfers between funds
A6 Cash funds last year end
Cash funds this year end
10,420
- 15,319 - - - 15,319 15,580
- - - - -
20,074 - - 20,074 4,494
4,755 - - 4,755 20,074

CCXX R1 accounts (SS)

20/10/2025

1

Section B Statement of assets and liabilities at the end of the period Section B Statement of assets and liabilities at the end of the period Section B Statement of assets and liabilities at the end of the period
Categories
Signed by one or two trustees on
behalf of all the trustees
B1 Cash funds
B2 Other monetary assets
B4 Assets retained for the
charity’s own use
B5 Liabilities
B3 Investment assets
Signature
Details
Bank
Details
Total cash funds
(agree balances with receipts and payments
account(s))
Details
Details
Details
Unrestricted
funds
Restricted
funds
to nearest £
to nearest £
4,755
-
-
-
-
-
4,755
-
OK
OK
Unrestricted
funds
Restricted
funds
to nearest £
to nearest £
-
-
-
-
-
-
-
-
-
-
-
-
Fund to which
asset belongs
Cost (optional)
-
-
-
-
-
Fund to which
asset belongs
Cost (optional)
-
-
-
-
-
-
-
-
-
Fund to which
liability relates
Amount due
(optional)
-
-
-
-
Print Name
E MARSHALL
Endowment
funds
to nearest £
-
-
-
-
OK
Endowment
funds
to nearest £
-
-
-
-
-
-
Current value
(optional)
-
-
-
-
-
Current value
(optional)
-
-
-
-
-
-
-
-
-
When due
(optional)
Date of
approval
E MARSHALL 24/10/2025

CCXX R2 accounts (SS)

20/10/2025

2